Association of TNFAIP3 With Immune-mediated TTP

Recruiting now · Not applicable

Conditions studied: Thrombotic Thrombocytopenic Purpura, Acquired

In brief

This study aims to investigate whether genetic variation in the TNFAIP3 locus is associated with immune-mediated thrombotic thrombocytopenic purpura (iTTP), and whether such association is mediated by decreased expression of A20 (TNFAIP3). The study includes a case-control design to assess genotype-expression association and a cohort study to evaluate clinical outcomes such as disease relapse.

Key facts

Study ID

NCT06928233

Run by

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

People needed

400

Starts

2025-04-07

Expected to finish

2026-04-01

Last updated by the study team

2026-03-27

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Diagnosis of iTTP
• Above 12 years of age
• Caucasian, Italian origin
• Written informed consent to participate in the study

You may not qualify if…

• Patients who do not meet the above-listed criteria will be excluded from participation in the study.
• Controls will be healthy Italian volunteers of Caucasian ethnicity, with no history of thrombotic thrombocytopenic purpura, frequency-matched to cases by age and sex, and who have provided written informed consent to participate in the study.

Where it is running

• Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico — Milan, Italy (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.